Ischemic and Bleeding Events After Early Initiation of Direct Oral Anticoagulants for Acute Intracranial Hemorrhage With Non-Valvular Atrial Fibrillation ― A Multicenter Prospective Registry ―
In Japanese patients with NVAF, early DOAC (re)initiation ≤14 days after ICH appears to have an acceptable risk for ischemic and hemorrhagic events, particularly in patients with intraparenchymal hemorrhage. In patients with subdural hematoma, early DOAC (re)initiation requires vigilant monitoring.
Authors
- Martin Unverdorben (ORCID: https://orcid.org/0000-0002-3601-8187)
- Kumiko Sugio
- Kaori Miwa
- Takahiro Ogishima (ORCID: https://orcid.org/0000-0003-0424-8129)
- Joji Hagii
- Tetsuya Kimura (ORCID: https://orcid.org/0000-0001-6367-7818)
- Yasushi Takagi (ORCID: https://orcid.org/0000-0002-9643-1272)
- Atsushi Takita
- Tatemi Todaka
- Nobukazu Komoribayashi (ORCID: https://orcid.org/0009-0002-9343-4862)
- N Sakai
- Kazutaka Sonoda (ORCID: https://orcid.org/0000-0002-1406-1336)
- Keiko Maezono-Kandori (ORCID: https://orcid.org/0000-0002-3761-0529)
- Makoto Hayase
- Hiroharu Kataoka (ORCID: https://orcid.org/0000-0001-8507-7557)
- Masanori Kinosada (ORCID: https://orcid.org/0000-0002-9935-5885)
- Yukako Yazawa
- Kuniyasu Wada
- Masatoshi Koga
- Yuka Terasawa
- Tsuyoshi Izumo
- Kanta Tanaka
- Rei Kondo
- Kunikazu Yoshimura
- Ryo Itabashi
- Hiroyuki Ohnishi
- Yasuhiro Ito
- Naoto Kimura
- Michikazu Nakai
- Yasuyuki Iguchi
- Masafumi Ihara
- Kazunori Toyoda
- on behalf of the SAFE-ICH Registry Group
- Fumio Miyashita
- Hiroshi Yamagami
- Hikaru Nagasawa
- Shouhei Noshiro
- Toshihiro Ueda
- Teruyuki Hirano
- Kazumi Kimura
- Shigeo Yamashiro
- Shigeru Fujimoto
- Ashkan Shoamanesh
Institutions
- Jikei University School of Medicine (JP)
- Kansai Medical University (JP)
- University of Tsukuba (JP)
- Jichi Medical University (JP)
- Hirosaki University (JP)
- St. Marianna University School of Medicine (JP)
- Daiichi Sankyo (Germany) (DE)
- Iwate Medical University (JP)
- Kyorin University (JP)
- Population Health Research Institute (CA)
- Kumamoto City Hospital (JP)
- Kurashiki Central Hospital (JP)
- Osaka National Hospital (JP)
- Iwate Prefectural Central Hospital (JP)
- Toyota Memorial Hospital (JP)
- Krankenhaus vom Roten Kreuz (DE)
- Saiseikai Kumamoto Hospital (JP)
- Daiichi Sankyo (United Kingdom) (GB)
- Red Cross Hospital (GR)
- Yamagata City Hospital Saiseikan (JP)
- Gifu University Hospital (JP)
- Japanese Red Cross Kumamoto Hospital (JP)
- National Cerebral and Cardiovascular Center (JP)
- Ohnishi Neurological Center (JP)
- Obihiro Kosei General Hospital (JP)
- Nakamura Memorial Hospital (JP)
- Kagoshima City Hospital (JP)
- Yamagata Prefectural Central Hospital (JP)
- Daiichi Sankyo (India) (IN)
- Nano Hydrophobics (United States) (US)
- University of Miyazaki Hospital (JP)
- Daiichi-Sankyo (South Korea) (KR)
- Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital (JP)
- Kohnan Hospital (JP)
- Saiseikai Fukuoka General Hospital (JP)
- Musashino Red Cross Hospital (JP)
- Nippon Steel Yawata Memorial Hospital (JP)
- Kokura Memorial Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Daiichi Sankyo (United States) (US)
- Iwate Prefectural University (JP)
- Nippon Medical School (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1253/circj.cj-25-0791
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Bayer
- CSL Behring
- Boston Scientific Corporation
- Stryker
- Abbott Japan
- Nihon Medi-Physics
- Japan Lifeline
- Kowa Company
- Boston Scientific Japan
- Boehringer Ingelheim Japan
- Nipro
- Daiichi-Sankyo
- Eisai
- Otsuka Pharmaceutical
- Servier
- Pfizer Japan
- Chugai Pharmaceutical
- Daiichi Sankyo Europe